The Austrian Immunoglobulin in MS (AIMS) study: final analysis.

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Observational studies and positive experiences in other autoimmune disorders suggest potential benefits of intravenous immunoglobulin (IVIG) for multiple sclerosis (MS).
• The efficacy of IVIG as an interval treatment for MS has not been rigorously evaluated in randomized controlled trials.

Purpose of the Study:

• To investigate the effectiveness of monthly IVIG treatment in patients with relapsing-remitting MS.
• To assess the impact of IVIG on disability progression, relapse frequency, and daily living in MS patients.

Main Methods:

• A randomized, double-blind, placebo-controlled trial (Austrian Immunoglobulin in Multiple Sclerosis - AIMS study) involving 148 patients with relapsing-remitting MS.
• Patients received monthly IVIG (0.15-0.2 g/kg bodyweight) or placebo for 2 years.
• Outcomes measured included Expanded Disability Status Scale (EDSS), relapse frequency, and patient-reported scales (Incapacity Status and Environmental Status Scales).

Main Results:

• IVIG treatment was associated with a significantly more favorable course of disability (EDSS change: -0.23 vs 0.12; P=0.008).
• A significant reduction in relapse frequency was observed in the IVIG group (0.52 vs 1.26; P=0.011).
• Beneficial effects were noted within 6 months and did not depend on baseline disability severity. Patient-reported outcomes on daily and social living also improved.

Conclusions:

• IVIG is a potential alternative treatment option for relapsing-remitting MS.
• Further research is warranted to determine the optimal usage and long-term benefits of IVIG for MS.
• IVIG demonstrated positive effects on disability, relapse rates, and quality of life in MS patients.